ArticleFrontiers in bioengineering and biotechnology2026
bFGF-genetically modified bone marrow-derived mesenchymal stem cells promote tendon-to-bone interface healing by promoting chondrogenesis and regulating macrophage polarization.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rapid regeneration and functional recovery of the enthesis following tendon-to-bone interface (TBI) injury remains a significant challenge. This study aims to investigate the feasibility of leveraging bFGF genetically modified bone marrow-derived mesenchymal stem cells (BMSCs) to enhance tendon-to-bone interface regeneration. Methods: The proliferation and chondrogenic differentiation effects of BMSCs after bFGF treatment were firstly studies Results: Conclusion: This study demonstrated that the employment of bFGF-transfected BMSCs accelerated tendon-to-bone regeneration by regulation of immune responses and promotion of fibrocartilage formation, thereby improving its healing quality of TBI injury. These findings suggested a novel and promising strategy by transfecting the BMSCs with bFGF gene for the treatment of TBI injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.